General Information of DTT (ID: TTE4BSY)

DTT Name Bromodomain and extraterminal domain protein (BET) DTT Info
Gene Name BET

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
21 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
CPI-0610 DMPXOYJ Myelofibrosis 2A20.2 Phase 3 [1]
ZEN-3694 DM6VQTF Prostate cancer 2C82.0 Phase 2 [2]
BMS-986158 DM6LDI4 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
INCB054329 DM7TZL0 Refractory hematologic malignancy 2A85.5 Phase 1/2 [3]
INCB057643 DMG65CV Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
ODM-207 DMOKVJD Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
OTX-015 DMI8RG1 Acute myeloid leukaemia 2A60 Phase 1/2 [1]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [6]
BAY 1238097 DMYPU8V Neoplasm 2A00-2F9Z Phase 1 [7]
BI 894999 DM7W5N2 Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
CC-90010 DMKH3Z9 Astrocytoma 2A00.0Y Phase 1 [1]
CC-95775 DMJCIGN Non-hodgkin lymphoma 2B33.5 Phase 1 [8]
FT-1101 DMZOAT3 Haematological malignancy 2B33.Y Phase 1 [1]
GS-5829 DMZVFOQ Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
GSK2820151 DMU1X8K Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
GSK525762 DMPAWBN Haematological malignancy 2B33.Y Phase 1 [1]
Mivebresib DMCPF90 Acute myeloid leukaemia 2A60 Phase 1 [1]
PLX51107 DMXLHVW Haematological malignancy 2B33.Y Phase 1 [1]
RG6146 DMIHC4R Haematological malignancy 2B33.Y Phase 1 [1]
RO6870810 DM7H6XI Multiple myeloma 2A83 Phase 1 [10]
ZEN003694 DM72GZV Prostate cancer 2C82.0 Phase 1 [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 21 Clinical Trial Drug(s)
37 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dihydropyrido pyrazinone compound 1 DM8S7NQ N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 1 DM5CXQT N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 10 DMAYKZ9 N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 11 DM1G8SM N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 12 DMVA8KL N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 13 DM7OBVT N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 14 DMS3CDT N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 15 DMPXK1C N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 16 DM614F8 N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 17 DM2SUCK N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 18 DME8CQA N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 19 DM01FD3 N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 2 DMYLR2S N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 3 DMWMRKJ N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 4 DMNI0PH N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 5 DMT46PS N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 6 DMKSNZG N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 7 DM3T840 N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 8 DM3IV7K N. A. N. A. Patented [11]
Isoxazole-based bicyclic compound 9 DMWA7RB N. A. N. A. Patented [11]
PMID26924192-Compound-50 DMTVZWM N. A. N. A. Patented [11]
PMID26924192-Compound-51 DMB2MH3 N. A. N. A. Patented [11]
PMID26924192-Compound-52 DMFU6JR N. A. N. A. Patented [11]
PMID26924192-Compound-53 DMFN1AR N. A. N. A. Patented [11]
PMID26924192-Compound-54 DMODT8F N. A. N. A. Patented [11]
PMID26924192-Compound-55 DMGWQVT N. A. N. A. Patented [11]
PMID26924192-Compound-56 DM6YGLT N. A. N. A. Patented [11]
PMID26924192-Compound-57 DM3NXP8 N. A. N. A. Patented [11]
Pyrimido-indole derivative 1 DMB5UF7 N. A. N. A. Patented [11]
Pyrimido-indole derivative 2 DM3REN5 N. A. N. A. Patented [11]
Pyrimido-indole derivative 3 DM53LGD N. A. N. A. Patented [11]
Quinazolinone derivative 3 DMDRIZF N. A. N. A. Patented [11]
Quinazolinone derivative 4 DM8WH97 N. A. N. A. Patented [11]
Quinazolinone derivative 5 DMXOKH3 N. A. N. A. Patented [11]
Tetra-hydro-quinoline derivative 2 DMEKO71 N. A. N. A. Patented [11]
Tetra-hydro-quinoline derivative 3 DMAWY4L N. A. N. A. Patented [11]
Tetra-hydro-quinoline derivative 4 DMMC3AG N. A. N. A. Patented [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 37 Patented Agent(s)
Molecule Interaction Atlas

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of Zenith Epigenetics.
3 The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies. Clin Cancer Res. 2019 Jan 1;25(1):300-311.
4 Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 Mar 15;26(6):1247-1257.
5 First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. Br J Cancer. 2020 Dec;123(12):1730-1736.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948.
8 Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
9 ClinicalTrials.gov (NCT02630251) Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors. U.S. National Institutes of Health.
10 A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021 Feb;124(4):744-753.
11 BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.